Hildur Helgadottir

Karolinska Institutet

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Collaborators (5)

Lars Ny

University of Gothenburg, Sahlgrenska Academy

Ana Carneiro

Lund University

Simon Ekman

Professor, Senior Consultant

Karolinska University Hospital

Kari Nielsen

Lund University

Håkan Olsson

Lund University

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hildur Helgadottir

Research Interests

Explore related searches

Contact this professor

Articles (14)

Collaborators (5)

Lars Ny

Ana Carneiro

Simon Ekman

Kari Nielsen

Håkan Olsson

Make your next move.

Hildur Helgadottir

Research Interests

Explore related searches

Contact this professor

Articles (14)

Germline MC1R Variant Status and Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Melanoma

Desmoplastic melanoma in Sweden in 2009–2022: A population‐based registry study demonstrating distinctive tumour characteristics, incidence and survival trends

Fertility and reproductive concerns related to the new generation of cancer drugs and the clinical implication for young individuals undergoing treatments for solid tumors

Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study

BAP1 genetic testing among melanoma and cancer-prone families in Sweden

Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Melanoma‐specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non‐carriers

Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and tolerability

Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers

Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study

Collaborators (5)

Lars Ny

Ana Carneiro

Simon Ekman

Kari Nielsen

Håkan Olsson

Make your next move.